Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel anti-DR5 antibody

A technology of antibodies and antigens, applied in the direction of antibodies, antibody medical components, antibody mimics/stents, etc., can solve problems such as no correlation

Inactive Publication Date: 2017-09-22
DAIICHI SANKYO CO LTD
View PDF24 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In order for such antibodies to have an antitumor effect, it is necessary that the cells express DR5, however, it has been revealed in preclinical tests that there is no correlation between the effect and the expression level of DR5 (Non-Patent Document 4)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel anti-DR5 antibody
  • Novel anti-DR5 antibody
  • Novel anti-DR5 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0393] [Example 1] Generation of mouse antibody B273

[0394] 1) Production of -1 human DR5 protein (human DR5 extracellular domain / human Fc fusion protein)

[0395] 1) Production of-1-1 human DR5 extracellular domain expression vector

[0396] A vector expressing human DR5 protein (isoform 2: NP_671716) was constructed by inserting a gene in which the extracellular domain of human DR5 was fused to the human IgG1 / Fc region downstream of the CMV promoter.

[0397] 1)-1-2 Production of human DR5 protein

[0398] Introduction of the expression vector into 293FreeStyle cells and collection of the culture supernatant were performed by Invitrogen Corporation (now Life Technologies Japan Ltd.).

[0399] 1)-1-3 Purification of human DR5 protein

[0400] The culture supernatant obtained in b) above was purified using protein A affinity column chromatography. 5 L of the culture supernatant was applied to "HiTrap Protein AFF" (GE Healthcare Bio-Sciences Co., Ltd., catalog number 17-5...

Embodiment 2

[0427] [Example 2] Cloning of mouse antibody B273 gene and production of human chimeric antibody gene

[0428] 2)-1 Cloning and sequence determination of mouse antibody B273 cDNA

[0429] 2) Determination of N-terminal amino acid sequences of heavy chain and light chain of -1-1 mouse antibody B273

[0430] In order to determine the N-terminal amino acid sequences of the heavy and light chains of the mouse antibody B273, the mouse antibody B273 purified in Examples 1-8 was separated by SDS-PAGE. After separation, the protein in the gel was transferred from the gel to a PVDF membrane (pore size: 0.45 μm, manufactured by Invitrogen Corporation). Membranes were washed with wash buffer (25 mM NaCl, 10 mM sodium borate buffer pH 8.0) and thereafter stained by immersion in dye solution (50% methanol, 20% acetic acid, 0.05% Coomassie Brilliant Blue) for 5 minutes, followed by destaining with 90% methanol . The band corresponding to the heavy chain (band with smaller mobility) and t...

Embodiment 3

[0471] [Example 3] Measurement of human chimeric B273 (cB273) antibody activity (in vitro)

[0472] 3) Selective binding properties of -1cB273 antibody to human DR5 extracellular domain

[0473] The binding properties of cB273 to human TRAIL R1-R4 and mouse TRAIL R2 extracellular domain proteins (manufactured by R&D Systems, Inc.) were investigated by the direct ELISA method described below. First, each of the ectodomain proteins of TRAIL R was diluted to 1 μg / ml with PBS, the diluted solution was dispensed in an immunoplate (manufactured by Nunc, Inc., #442404) at 50 μl / well, and the plate was kept at 4°C By standing overnight, the protein is thus adsorbed to the plate. The next day, the liquid in each well was removed, and each well was washed once with PBS. Thereafter, in order to suppress nonspecific adsorption of proteins, 200 µl / well of PBS containing 3% fetal bovine serum was dispensed, and the plate was allowed to stand at room temperature for 1.5 hours. The liquid ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an antibody which has a therapeutic effect on cancer, autoimmune diseases or inflammatory diseases. Namely, the present invention relates to an antibody which exhibits an apoptosis-mediated cytotoxic activity on a cell expressing a death domain-containing receptor. The present invention addresses the problem of providing a drug which has a therapeutic effect on cancer. The present invention clarifies that a novel anti-DR5 antibody, which is capable of inducing apoptosis in a cell, has a remarkable cytotoxic activity compared with the conventional anti-DR5 antibodies.

Description

[0001] This application is a divisional application of the national application number 201180063500.4 (PCT / JP2011 / 074866) filed on October 27, 2011 entitled "New Anti-DR5 Antibody". [technical field] [0002] The present invention relates to an antibody that binds to a cell surface receptor involved in the induction of apoptosis and can be used as a tumor therapeutic and / or preventive agent, and also relates to the use of the antibody for the treatment and / or prevention of cancer, autoimmune disease or inflammatory disease method. [Background technique] [0003] Apoptosis is a phenomenon essential to the physiological process of removing unnecessary or damaged cells in the body while maintaining normal cell numbers. New cells that can be used for the treatment of cancer or immune diseases due to the elucidation of the fact that the regulatory mechanisms of apoptosis are often impaired in cancer or immune diseases, and also the elucidation of the regulatory pathways of apopto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K16/30A61K31/337A61K31/439A61K31/4545A61K31/4745A61K31/475A61K31/513A61K31/555A61K39/395A61K45/06A61P35/00
CPCA61K31/337A61K31/439A61K31/4545A61K31/4745A61K31/475A61K31/513A61K31/555A61K39/3955A61K39/39558A61K45/06C07K16/2878C07K16/30A61K2039/505A61K2300/00C07K2299/00C07K2317/92C07K2319/30C07K2317/24C07K2317/55C07K2317/515C07K2317/51C07K2317/34C07K2317/73C07K14/70578A61P35/00A61P43/00A61K38/17A61K38/18A61K39/395A61K48/00C07K14/435C07K14/475C07K16/18C07K16/22C07K16/24C07K16/28C07K19/00
Inventor 大塚敏明泷泽刚小国晶子松冈达司好田宏子松井由美
Owner DAIICHI SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com